The current price of VRDN is $29.06 — it has increased by 15.53% since the previous close. Data as of Nov 4, 2026.
VRDN is up 17.30% over the past week, up 49.77% over the past month and up 28.85% over the past year. The price is above its 200-day moving average of $21.68.
Of the 17 analysts covering Viridian Therapeutics, Inc., 3 rate it a strong buy and 14 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Viridian Therapeutics, Inc. has a market capitalization of $3.29B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Viridian Therapeutics, Inc. posted a loss of $0.81 per share against an estimate of -$1.02, beating expectations by 20.59%. Upcoming reports are listed in the earnings calendar.
Viridian Therapeutics, Inc. reported revenue of $25.75M in its most recent quarter, which has decreased by 63.51% compared with the same quarter a year earlier. Analysts had expected $4.72M.
Viridian Therapeutics, Inc. has not paid any dividends over the past year.
In the latest trading session VRDN moved between $25.10 and $29.63, a range of 15.57% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Viridian Therapeutics, Inc. shows a strong buy rating today and a strong buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Viridian Therapeutics, Inc. is strong buy. Technical ratings are indicators, not investment advice.
Over the past 52 weeks VRDN has traded between $13.18 and $34.29. The current price is 15.27% below its 52-week high.
Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.